University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 0C-18-22


A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination with MGA012, an anti-PD-1 antibody, in Patients with Relapsed or Refractory B7-H3-Expressing Tumors

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments:
Randomized: Not Asked
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Rishi Bhavsar, Coordinator, Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Taison Tran, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Negeen Izadian, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.